
|Articles|March 12, 2014
- Immunotherapy (Issue 2)
- Volume 2
- Issue 1
The Future of Immunotherapy Treatments in Lung Cancer
Author(s)Balazs Halmos, MD
Balazs Halmos, MD, section chief of Thoracic Oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the future of immunotherapy treatments.
Advertisement
Balazs Halmos, MD, section chief of Thoracic Oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the future of immunotherapy treatments in lung cancer.
Read more about immunotherapies for lung and other cancers > >
Articles in this issue
over 11 years ago
The Outlook for CAR-Modified T Cellsover 11 years ago
B-Cell Malignancies Faring Well With Immunotherapiesover 11 years ago
Update on Immunotherapy and Targeted Combination Therapiesover 11 years ago
How Immunotherapies are Changing the Treatment of Melanomaover 11 years ago
Progress Made With PD-L1 as Predictive Biomarkerover 11 years ago
Oncolytic Viral Therapies About to Spreadover 11 years ago
Checking in on Checkpoint InhibitorsAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5









































